PCI Biotech Holding ASA (OSL:PCIB) Cyclically Adjusted Book per Share: kr2.52 (As of Jun. 2025)


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA Cyclically Adjusted Book per Share?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Cyclically Adjusted Book per Share is kr2.52 as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

PCI Biotech Holding ASA's adjusted book value per share data for the fiscal year that ended in Dec. 2024 was kr0.628. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr2.52 for the trailing ten years ended in Dec. 2024.

During the past 12 months, PCI Biotech Holding ASA's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of PCI Biotech Holding ASA was 2.90% per year. The lowest was -7.90% per year. And the median was -3.50% per year.

As of today (2026-07-04), PCI Biotech Holding ASA's current stock price is kr 0.115. PCI Biotech Holding ASA's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2024 was kr2.52. PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PCI Biotech Holding ASA was 0.02. The lowest was 0.00. And the median was 0.00.


PCI Biotech Holding ASA  (OSL:PCIB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.115/2.52
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PCI Biotech Holding ASA was 0.02. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


PCI Biotech Holding ASA Cyclically Adjusted Book per Share Related Terms


PCI Biotech Holding ASA Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Cyclically Adjusted Book per Share Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.70 5.24 3.11 2.80 2.52

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.88 2.80 3.78 2.52 0.00

OSL:PCIB vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Cyclically Adjusted PB Ratio falls into.


OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PCI Biotech Holding ASA's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2024 was:

Adj_Book=Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.628/134.8000*134.8000
=0.628

Current CPI (Dec. 2024) = 134.8000.

PCI Biotech Holding ASA Annual Data

Book Value per Share CPI Adj_Book
201512 2.064 100.900 2.757
201612 0.815 104.400 1.052
201712 1.555 106.100 1.976
201812 9.147 109.800 11.230
201912 6.838 111.300 8.282
202012 5.070 112.900 6.053
202112 3.049 118.900 3.457
202212 1.538 125.900 1.647
202312 1.046 131.900 1.069
202412 0.628 134.800 0.628

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr2.52 mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Cyclically Adjusted Book per Share of kr2.52 as of Jun. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Cyclically Adjusted Book per Share too high?
PCI Biotech Holding ASA's current Cyclically Adjusted Book per Share is kr2.52. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Cyclically Adjusted Book per Share compare to VRTX and REGN?
PCI Biotech Holding ASA's Cyclically Adjusted Book per Share of kr2.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Cyclically Adjusted Book per Share is kr2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Cyclically Adjusted Book per Share of kr2.52. The current Cyclically Adjusted Book per Share is kr2.52. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Cyclically Adjusted Book per Share is kr2.52 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price